[HTML][HTML] Mild or moderate Covid-19
Key Clinical Points Mild or Moderate Covid-19 Covid-19 has a range of clinical
manifestations, including cough, fever, myalgias, gastrointestinal symptoms, and anosmia …
manifestations, including cough, fever, myalgias, gastrointestinal symptoms, and anosmia …
[HTML][HTML] Severe covid-19
Key Clinical Points Evaluation and Management of Severe Covid-19 Patients with severe
coronavirus disease 2019 (Covid-19) may become critically ill with acute respiratory distress …
coronavirus disease 2019 (Covid-19) may become critically ill with acute respiratory distress …
Remdesivir for the treatment of Covid-19—preliminary report
BACKGROUND: Although several therapeutic agents have been evaluated for the treatment
of coronavirus disease 2019 (Covid-19), no antiviral agents have yet been shown to be …
of coronavirus disease 2019 (Covid-19), no antiviral agents have yet been shown to be …
[HTML][HTML] Medical management of COVID-19: evidence and experience
Coronavirus disease 2019 is caused by severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), and this infectious disease is termed COVID-19 in short. On a global scale …
(SARS-CoV-2), and this infectious disease is termed COVID-19 in short. On a global scale …
Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review
Importance The coronavirus disease 2019 (COVID-19) pandemic, due to the novel severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused a worldwide sudden …
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused a worldwide sudden …
Improved survival among hospitalized patients with coronavirus disease 2019 (COVID-19) treated with remdesivir and dexamethasone. A nationwide population …
T Benfield, J Bodilsen, C Brieghel… - Clinical Infectious …, 2021 - academic.oup.com
Background There are limited data on outcomes of moderate to severe coronavirus disease
2019 (COVID-19) among patients treated with remdesivir and dexamethasone in a real …
2019 (COVID-19) among patients treated with remdesivir and dexamethasone in a real …
[HTML][HTML] COVID-19: An overview and a clinical update
A Krishnan, JP Hamilton, SA Alqahtani… - World journal of clinical …, 2021 - ncbi.nlm.nih.gov
The outbreak of coronavirus disease-2019 (COVID-19, previously known as 2019 nCoV)
caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in …
caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in …
[HTML][HTML] Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial
CD Spinner, RL Gottlieb, GJ Criner, JRA López… - Jama, 2020 - jamanetwork.com
Importance Remdesivir demonstrated clinical benefit in a placebo-controlled trial in patients
with severe coronavirus disease 2019 (COVID-19), but its effect in patients with moderate …
with severe coronavirus disease 2019 (COVID-19), but its effect in patients with moderate …
Real-world effectiveness of remdesivir in adults hospitalized with coronavirus disease 2019 (COVID-19): a retrospective, multicenter comparative effectiveness study
Background There is an urgent need to understand the real-world effectiveness of
remdesivir in the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV …
remdesivir in the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV …
[HTML][HTML] Remdesivir for the treatment of Covid-19
Background Although several therapeutic agents have been evaluated for the treatment of
coronavirus disease 2019 (Covid-19), no antiviral agents have yet been shown to be …
coronavirus disease 2019 (Covid-19), no antiviral agents have yet been shown to be …